Swiss Garnier Laboratories Profile
Key Indicators
- Authorised Capital ₹ 3.50 M
as on 24-10-2024
- Paid Up Capital ₹ 1.36 M
as on 24-10-2024
- Company Age 22 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2023)
- Ebitda
- Net Worth
- Total Assets 2.63%
(FY 2023)
About Swiss Garnier Laboratories
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.50 M and a paid-up capital of Rs 1.36 M, as per Ministry of Corporate Affairs (MCA) records.
Muthu Subramanian and Rethinavalli Theivendran serve as directors at the Company.
- CIN/LLPIN
U24232TN2002PTC049296
- Company No.
049296
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Jul 2002
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Kanchipuram, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Swiss Garnier Laboratories?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Muthu Subramanian  | Managing Director | 07-Oct-2003 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Rethinavalli Theivendran | Director | 07-Oct-2003 | Current |
Financial Performance of Swiss Garnier Laboratories.
Swiss Garnier Laboratories Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Swiss Garnier Laboratories?
In 2022, Swiss Garnier Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Swiss Garniers Genexiaa Sciences Private LimitedActive 6 years 5 monthsMuthu Subramanian and Rethinavalli Theivendran are mutual person
- Swiss Garnier Health Sciences Private LimitedActive 12 years 10 months
Muthu Subramanian and Rethinavalli Theivendran are mutual person
- Swiss Garniers Biotech Private LimitedActive 6 years 5 months
Muthu Subramanian and Rethinavalli Theivendran are mutual person
- Swiss Garnier Hospitals And Enterprises Private LimitedActive 8 years 7 months
Muthu Subramanian and Rethinavalli Theivendran are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Swiss Garnier Laboratories?
Unlock and access historical data on people associated with Swiss Garnier Laboratories, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Swiss Garnier Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Swiss Garnier Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
